We aim to change
A drug with the potential to optimise the fight against iron deficiency
Ferric bepectate is a patented total-dosage iron therapy with a unique formulation and a promising pharmacokinetic profile. Unlike some currently available IV iron formulations, our product is based on a specific modified starch rather than dextran. Once approved and launched, ferric bepectate will offer a therapy option in the market for IV iron treatments that are capable of providing the high doses demanded by current deficiency levels worldwide – without compromising patient safety.
More than 30% of the global population are anaemic1
Anaemia affects roughly a third of the world’s population; half the cases are due to iron deficiency1. According to the World Health Organization (WHO), iron deficiency is the most common and widespread nutritional disorder of all2,3. Many diseases compromise human health by causing or contributing to anaemia and iron deficiency.
1. Antony Lopex et al., The Lancet Seminar 2016| Volume 387, ISSUE 10021, P907-916, February 27 2016 DOI:https://doi.org/10.1016/S0140-6736(15)60865-0
A unique business opportunity
Iron deficiency remains a challenge of epidemic proportions to human health worldwide. Ferric bepectate will fill a significant gap in the market for high dose IV iron treatments. Iron4u’s future plans include establishing a network of strong specialty-pharmaceutical companies that are capable of exploring the huge potential of our ferric bepectate product and supporting solutions for clinicians who use IV iron therapy, over many therapeutic areas.
Global market opportunities
Iron deficiency remains a significant challenge to human health worldwide, diminishing in many ways the quality of life for billions of people. The high levels of unmet need for iron deficiency therapy worldwide suggest a wealth of opportunities for rapid growth with the right product that offers significant advantages. Intravenous iron sales in the US alone are set to reach $1 billion in 2019. In the longer term, the US market could be worth more than $5 billion.
“Anemia affects roughly a third of the world’s population; half the cases are due to iron deficiency”
“Despite recent advances in IV iron therapies – we are still awaiting the ultimate IV iron formulation that allows a rapid iron repletion without releasing labile iron, which is thought to be responsible for most of IV iron infusion reactions and may expose the patient to the risk of oxidative stress from free iron radicals”
“In iron4u, we strongly believe that ferric bepectate has the potential to redefine IV iron therapy”
The iron4u team consist of a group of pharmaceutical professions of senior ranking, most with 20 years plus experience at Director and Senior management positions, primarily in pharmaceutical companies. Several team members have more than 20 years experience in the human and veterinarian injectable iron business.
The vision of iron4u is to improve the care of iron deficiency and iron deficiency anaemia through the development and introduction of new innovative iron therapy solutions – building on the vast amount of evidence and learnings from 50+ years of experience with oral and parenteral iron therapy.
It is iron4u’s mission to introduce a new parenteral treatment solution for iron deficiency anemia that will solve some of the historical shortcomings of parenteral iron compounds, offering an attractive, well documented and cost-effective solution for combating iron deficiency anemia in all sectors of society – changing the future of iv iron therapy.